All posts tagged ross camidge

  • Camidge.Slider.940x530

    Promising trial results of brigatinib show that all next-gen ALK inhibitors may not be created equal

    Phase I/II clinical trial results reported at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 show promising results for investigational drug brigatinib against ALK+ non-small cell lung cancer (NSCLC), with 58 of 78 ALK+ patients responding to treatment, including 50 of 70 patients who had progressed after previous treatment with crizotinib, the first licensed ALK inhibitor.

money
Economics influence cancer treatment decisions. But are the numbers as solid as they seem? Image: Flickr/Simon Cunningham cc license.
wilmot2
feature
7511985228_f25433830a_o
Camidge.Slider.940x530
Ross Camidge, MD, chief of the Lung Cancer program at
the University of Colorado Cancer Center, helped to enroll Rabinowitz
in the phase 1 trial of a new ALK inhibitor.
Camidge
Ross Camidge, MD, PhD